Lion Biotechnologies Names Molly Henderson Chief Financial Officer Read more about Lion Biotechnologies Names Molly Henderson Chief Financial Officer
Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma Read more about Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
Lion Biotechnologies to Join Russell Global Index Read more about Lion Biotechnologies to Join Russell Global Index
Lion Biotechnologies Announces Second Quarter 2015 Financial Results Read more about Lion Biotechnologies Announces Second Quarter 2015 Financial Results
Lion Biotechnologies Announces Strategic Hires Read more about Lion Biotechnologies Announces Strategic Hires
Lion Biotechnologies to Participate in Upcoming Investor and Scientific Conferences Read more about Lion Biotechnologies to Participate in Upcoming Investor and Scientific Conferences
Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma Read more about Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma
Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma Read more about Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers Read more about Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers
Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi Read more about Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi